ELEVANCE HEALTH: UBS Lowers Price Target to $400 from $425
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6h ago
0mins
Source: moomoo
- Price Adjustment: The target price for Elevance Health's stock has been reduced from $425 to $400.
- Market Impact: This adjustment reflects changes in market conditions and expectations for the company's performance.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ELV
Wall Street analysts forecast ELV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELV is 392.07 USD with a low forecast of 320.00 USD and a high forecast of 431.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
11 Buy
4 Hold
0 Sell
Moderate Buy
Current: 341.850
Low
320.00
Averages
392.07
High
431.00
Current: 341.850
Low
320.00
Averages
392.07
High
431.00
About ELV
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elevance Health Sets 2026 EPS Guidance Amid Membership Declines
- 2026 EPS Guidance: Elevance Health has set a target for adjusted diluted earnings per share of at least $25.50 for 2026, despite 2025 results including approximately $3.75 per share from favorable nonrecurring items, indicating a cautious approach amidst challenges.
- Medicaid Business Outlook: CEO Gail Boudreaux highlighted that the Medicaid segment is expected to experience an operating margin of approximately negative 1.75% in 2026, reflecting a focus on long-term sustainability with ongoing rate adjustments and program design changes.
- Medicare Membership Decline: The company anticipates a decline in Medicare Advantage membership in the high teens percentage range for 2026, a strategic move aimed at improving margins, although this may exert short-term pressure on revenues.
- Financial Performance Review: Elevance reported adjusted diluted EPS of $3.33 for Q4 and operating revenue of $49.3 billion for the full year, marking a 10% year-over-year increase, demonstrating robust financial performance under challenging market conditions.
Continue Reading
ELEVANCE HEALTH STOCK RECOVERS FROM PREMARKET DECLINE, RISING 3.23% FOLLOWING Q4 RESULTS REPORT
- Market Performance: Elevance Health shares experienced a decline of 3.23% following the release of their Q4 results.
- Core Reports Impact: The drop in stock value is attributed to the core reports that were released, which likely influenced investor sentiment.
Continue Reading